Conformis logo
Conformis CFMS
report update icon

Quarterly report 2023-Q2
added 05-16-2026

Conformis Financial Ratios 2022-2011 | CFMS

Brief overview of Conformis's financial ratios

Ratios are assessed across five available annual reports in the 2018–2022 interval.

The latest available valuation ratios are P/S 0.2x (median 1.05x), P/B 0.23x (median 2x). Valuation is roughly 84.5% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

Returns on assets and capital are represented by ROE -93.2%, ROA -53.7%, ROCE -85.4%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

A shorter cycle, from 264.4 days to 165.4 days, indicates faster release of cash from operations.

Valuation takeaway

Conformis trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.

Annual Financial Ratios Conformis

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.3 -1.8 -3.0 -9.2 -7.3 -5.0 -3.6 -3.5 - - - -

P/S

0.2 0.0 1.1 2.5 3.3 2.8 9.6 3.0 - - - -

EPS

-7.0 -0.4 -0.3 -0.4 -0.7 -1.2 -1.4 -2.6 -10.8 -12.0 - -

EV (Enterprise Value)

3.84 M -51.5 M 104 M 79.6 M 82.8 M 87.9 M 190 M 101 M -16.4 M -39.3 M - -

EBITDA per Share

-5.85 0.19 -0.29 -0.33 -0.59 -1.2 -1.28 -2.43 -10.2 -11.4 - -

EV/EBITDA

-0.1 -40.7 -5.0 -3.8 -2.4 -1.7 -3.6 -1.9 0.4 0.9 - -

PEG

0.0 0.03 0.09 0.2 0.19 -0.11 -0.13 0.06 - - - -

P/B

0.2 0.0 6.4 3.1 2.0 1.3 2.2 1.4 - - - -

P/CF

-0.3 -0.5 -4.0 -17.6 -2.9 -1.5 -6.0 -4.1 - - - -

ROE %

-93.16 -2.40 -213.62 -33.24 -27.27 -25.49 -61.23 -40.54 -91.76 -69.44 - -

ROA %

-53.67 -1.66 -33.98 -7.50 -15.67 -12.64 -51.05 -35.92 -64.15 -57.08 - -

ROCE %

-85.42 -2.99 -61.88 -46.07 -74.97 -69.05 -56.98 -38.27 -75.15 -67.15 - -

Current Ratio

2.4 3.2 1.2 1.3 2.4 2.0 6.0 8.8 3.3 5.6 - -

DSO

55.4 32.1 52.0 223.0 218.5 245.2 248.8 65.4 34.5 - - -

DIO

160.3 148.4 128.4 96.9 82.7 77.4 79.7 77.7 43.4 - - -

DPO

50.4 61.3 61.6 46.5 36.8 38.4 35.0 33.7 20.4 - - -

Operating Cycle

215.8 180.5 180.4 319.9 301.2 322.5 328.5 143.2 77.9 - - -

Cash Conversion Cycle

165.4 119.2 118.8 273.4 264.4 284.2 293.5 109.5 57.5 - - -

All numbers in USD currency

Quarterly Financial Ratios Conformis

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.78 -1.32 - -0.08 -0.09 -0.09 - -0.07 0.21 -0.09 -0.08 -0.09 -0.03 -0.14 -0.08 -0.13 -0.11 -0.12 -0.16 -0.12 -0.24 -0.22 -0.27 -0.29 -0.28 -0.4 -0.37 -0.31 -0.34 -0.37 -0.37 -0.45 -2.51 -3.32 -2.83 -2.44 -2.49 -3.04 - - - - - - - - - - - -

EBITDA per Share

-1.43 -1.17 - -0.05 -0.06 -0.08 - -0.05 0.19 -0.06 - -0.05 - -0.1 - -0.06 -0.06 -0.09 - -0.06 -0.16 -0.21 - -0.23 -0.28 -0.38 - -0.25 -0.3 -0.35 - -0.38 -2.23 -3.15 - -2.06 -2.24 - - - - - - - - - - - - -

ROE %

-108.07 -86.08 -64.64 -75.95 -20.84 -12.87 5.77 -52.46 -74.03 -129.57 -214.69 -189.70 -200.54 -200.03 -126.68 -120.71 -94.10 -97.92 -92.87 -91.10 -95.90 -85.02 -86.63 -77.87 -68.14 -62.57 -52.79 -46.67 -45.51 -72.92 -71.28 -85.01 -94.85 -76.46 -24.34 -20.86 -21.16 - - - - - - - - - - - - -

ROA %

-58.65 -51.90 -40.22 -48.45 -11.38 -6.02 6.43 -2.83 -2.33 -28.03 -34.87 -33.11 -37.25 -44.50 -41.59 -49.75 -46.50 -51.02 -50.74 -47.71 -51.05 -46.55 -50.09 -51.40 -50.03 -50.41 -45.58 -41.03 -40.29 -48.31 -47.02 -54.63 -59.37 -55.34 -17.02 -14.59 -14.79 - - - - - - - - - - - - -

ROCE %

-96.52 -75.23 -54.10 -64.01 -19.84 -12.95 4.19 -33.41 -50.70 -160.14 -149.66 -184.09 -168.07 -162.57 -77.70 -92.69 -81.35 -80.43 -58.73 -81.42 -86.80 -85.45 -64.79 -77.11 -66.61 -58.07 -36.33 -46.78 -73.93 -71.70 -59.88 -80.61 -91.27 -9.96 - -20.73 -21.11 - - - - - - - - - - - - -

Current Ratio

1.9 2.2 2.4 2.4 2.7 3.0 3.2 3.7 3.9 2.5 1.2 1.3 1.1 1.2 1.3 1.4 1.7 1.9 2.4 2.0 2.1 2.4 2.0 2.2 2.4 3.3 6.0 7.7 9.1 7.9 8.8 9.3 1.9 8.8 3.3 3.3 3.3 - - - - - - - - - - - - -

DSO

56.9 65.1 - 62.9 58.7 56.4 - 57.1 13.9 55.1 47.8 48.6 38.3 53.4 49.5 57.3 56.5 57.9 51.5 37.6 58.1 58.7 56.7 60.6 61.5 61.9 60.0 65.9 62.8 64.0 55.3 63.3 61.5 74.5 58.5 69.3 37.2 - - - - - - - - - - - - -

DIO

157.1 226.5 - 177.6 150.2 143.5 - 154.7 138.6 154.4 - 141.1 135.2 117.9 - 104.7 92.4 80.6 - 94.2 78.7 72.9 - 91.8 86.4 75.5 - 85.6 81.8 80.9 - 88.4 89.4 93.4 - 95.5 49.4 - - - - - - - - - - - - -

DPO

31.6 49.1 - 70.2 57.2 54.5 - 55.8 51.6 59.1 - 64.1 68.2 64.6 - 41.4 39.5 33.3 - 51.5 47.4 39.0 - 38.6 40.4 36.7 - 23.9 27.2 36.1 - 45.8 39.5 40.5 - 44.9 23.3 - - - - - - - - - - - - -

Operating Cycle

213.9 291.7 - 240.5 208.9 199.9 - 211.8 152.5 209.5 46.5 184.3 175.8 175.8 50.9 172.2 162.0 144.8 54.7 135.6 150.4 139.9 58.0 140.8 133.7 130.5 61.8 156.4 149.5 144.6 71.1 192.1 162.8 167.8 58.5 164.8 86.7 - - - - - - - - - - - - -

Cash Conversion Cycle

182.3 242.5 - 170.3 151.7 145.4 - 156.0 100.9 150.4 46.5 131.1 122.7 117.5 50.9 107.0 98.7 101.1 54.7 101.7 118.9 105.0 58.0 100.6 97.2 96.6 61.8 116.9 112.0 110.4 71.1 153.4 125.0 127.3 58.5 119.9 63.4 - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Conformis, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Myomo Myomo
MYO
$ 1.01 1.0 % $ 42.3 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
InspireMD InspireMD
NSPR
$ 0.65 -3.68 % $ 41.8 M israelIsrael
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.38 1.79 % $ 223 M canadaCanada
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.48 -1.14 % $ 148 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.4 -2.0 % $ 123 M australiaAustralia
AxoGen AxoGen
AXGN
$ 42.21 2.08 % $ 1.94 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 62.84 -2.33 % $ 9.54 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 31.56 -2.46 % $ 27.4 B britainBritain
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 28.17 -0.11 % $ 644 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.73 2.83 % $ 34.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.5 2.58 % $ 1.33 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.67 -0.77 % $ 454 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.94 2.47 % $ 423 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 11.19 1.08 % $ 463 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Inogen Inogen
INGN
$ 6.45 0.47 % $ 172 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.36 3.08 % $ 22.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.82 -1.39 % $ 13.9 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 121.21 20.18 % $ 4.21 B usaUSA
Beyond Air Beyond Air
XAIR
$ 5.28 -2.68 % $ 43.8 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 -0.6 % $ 60 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.14 -1.12 % $ 4.37 B britainBritain
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA